Molecular Partners AG
MOLN
Rank in Stocks
#18859
Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to... Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and bringing to market novel therapeutic proteins. Leveraging its proprietary DARPin® platform, the company is advancing a diverse pipeline of product candidates. Key among these is Abicipar, a DARPin-based treatment currently in Phase III clinical development for significant ophthalmic conditions like neovascular wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Additionally, their portfolio features multi-specific DARPin candidates targeting infectious diseases, such as MP0420 and MP0423, both designed to combat the SARS-CoV-2 virus (COVID-19). In the oncology space, Molecular Partners is advancing several programs: MP0310, in Phase Ia for immuno-oncology; MP0317, a Phase I tumor-localized immune agonist engineered to activate immune cells within tumors; and MP0274, also in Phase I, aimed at HER2-positive cancers. Further early-stage assets include MP0533, a CD3 T cell candidate for acute myeloid leukemia, and MP0250, which targets vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and human serum albumin (HSA) to enhance therapeutic half-life. The company actively collaborates with leading pharmaceutical companies. Notable alliances include a partnership with Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; agreements with Amgen SA and Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc. They also maintain relationships with various other third-party collaborators. Established in 2004, Molecular Partners AG is headquartered in Schlieren, Switzerland.
Share Price
$3.15
Last synced: 2026-11-09
Market Cap
$120.65M
Change (1 day)
-0.81%
Change (1 year)
-18.74%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Molecular Partners AG (MOLN)
Category
Healthcare
Operating Margin for Molecular Partners AG (MOLN)
Operating Margin as of November 2026 TTM: 0.00%
According to Molecular Partners AG's latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Molecular Partners AG from 2013 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | -100.00% |
| 2024 | -1,231.73% | 41.86% |
| 2023 | -868.26% | -1,511.35% |
| 2022 | 61.52% | -109.05% |
| 2021 | -679.72% | 8.89% |
| 2020 | -624.21% | 247.05% |
| 2019 | -179.86% | -50.21% |
| 2018 | -361.27% | 179.79% |
| 2017 | -129.12% | 52.68% |
| 2016 | -84.57% | 1,009.84% |
| 2015 | -7.62% | -210.27% |
| 2014 | 6.91% | -68.52% |
| 2013 | 21.95% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Molecular Partners AG's operating margin
What was Molecular Partners AG's operating margin in 2025?
In 2025, Molecular Partners AG's operating margin was 0.00%, compared with -1,231.73% in 2024.
How has Molecular Partners AG's operating margin changed since 2020?
From 2020 to 2025, Molecular Partners AG's operating margin was highest in 2022 (61.52%) and lowest in 2024 (-1,231.73%).
How does Molecular Partners AG's operating margin compare with similar companies?
Molecular Partners AG's operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.